An update on the pharmacological management of adenomyosis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 16, 2014, Pages 2347-2360

  Streuli, Isabelle ^a   Dubuisson, Jean ^a   Santulli, Pietro ^b   De Ziegler, Dominique ^b   Batteux, Frédéric ^c   Chapron, Charles ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Abnormal uterine bleeding; Adenomyosis; Dysmenorrheal; Hormonal treatment; Infertility; Medical treatment

Indexed keywords

AROMATASE INHIBITOR; BROMOCRIPTINE; DANAZOL; DIENOGEST; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEVONORGESTREL; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; ULIPRISTAL; ANGIOGENESIS INHIBITOR; GONADORELIN; GONADORELIN RECEPTOR;

ABNORMAL UTERINE BLEEDING; ADENOMYOSIS; ADENOMYOSIS RELATED PAIN; ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; CELL INFILTRATION; DIAGNOSTIC ACCURACY; DYSMENORRHEA; EMBRYO TRANSFER; EPIGENETICS; FREEZE THAWING; HUMAN; HUMORAL IMMUNITY; HYSTERECTOMY; INFERTILITY; INFERTILITY THERAPY; NONHUMAN; OOCYTE DONATION; PAIN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PREGNANCY RATE; PREMEDICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UTERUS BLEEDING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMPLICATION; FEMALE; INFERTILITY, FEMALE; METRORRHAGIA; PATHOPHYSIOLOGY; PELVIC PAIN;

ADENOMYOSIS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; METRORRHAGIA; PELVIC PAIN; PROGESTINS; RECEPTORS, LHRH; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 84911463979     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.953055     Document Type: Review

References (93)

1. Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20(4):511-21
2. Uduwela AS, Perera MA, Aiqing L, et al. Endometrial-myometrial interface: relationship to adenomyosis and changes in pregnancy. Obstet Gynecol Surv 2000;55(6):390-400
3. Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update 1998;4(4):312-22
4. Bazot M, Cortez A, Darai E, et al. Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod 2001;16(11):2427-33
5. Dueholm M. Transvaginal ultrasound for diagnosis of adenomyosis: a review. Best Pract Res Clin Obstet Gynaecol 2006;20(4):569-82
6. Exacoustos C, Brienza L, Di Giovanni A, et al. Adenomyosis: three-dimensional sonographic findings of the junctional zone and correlation with histology. Ultrasound Obstet Gynecol 2011;37(4):471-9
7. Gordts S, Brosens JJ, Fusi L, et al. Uterine adenomyosis: a need for uniform terminology and consensus classification. Reprod Biomed Online 2008;17(2):244-8
8. Fernández C, Ricci P, Fernández E. Adenomyosis visualized during hysteroscopy. J Minim Invasive Gynecol 2007;14(5):555-6
9. Molinas CR, Campo R. Office hysteroscopy and adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20(4):557-67
10. Tocci A, Greco E, Ubaldi FM. Adenomyosis and "endometrialsubendometrial myometrium unit disruption disease" are two different entities. Reprod Biomed Online 2008;17(2):281-91
11. Bazot M, Fiori O, Darai E. Adenomyosis in endometriosis-prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod 2006;21(4):1101-2; author reply 1102-1103
12. Kunz G, Beil D, Huppert P, et al. Adenomyosis in endometriosis-prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod 2005;20(8):2309-16
13. Indraccolo U, Barbieri F. Relationship between adenomyosis and uterine polyps. Eur J Obstet Gynecol Reprod Biol 2011;157(2):185-9
14. Larsen SB, Lundorf E, Forman A, et al. Adenomyosis and junctional zone changes in patients with endometriosis. Eur J Obstet Gynecol Reprod Biol 2011;157(2):206-11
15. Lazzeri L, Di Giovanni A, Exacoustos C, et al. Preoperative and postoperative clinical and transvaginal ultrasound findings of adenomyosis in patients with deep infiltrating endometriosis. Reprod Sci 2014;21(8):1027-33
16. Benagiano G, Habiba M, Brosens I. The pathophysiology of uterine adenomyosis: an update. Fertil Steril 2012;98(3):572-9
17. Zhou S, Yi T, Liu R, et al. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics 2012;11(7):M112.017988
18. Huang TS, Chen YJ, Chou TY, et al. Oestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. J Cell Mol Med 2014;18(7):1358-71
19. Greaves P, White IN. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20(4):503-10
20. Benagiano G, Brosens I, Habiba M. Structural and molecular features of the endomyometrium in endometriosis and adenomyosis. Hum Reprod Update 2014;20(3):386-402
21. Leyendecker G, Wildt L, Mall G. The pathophysiology of endometriosis and adenomyosis: tissue injury and repair. Arch Gynecol Obstet 2009;280(4):529-38
22. Ota H, Igarashi S, Hatazawa J, et al. Is adenomyosis an immune disease? Hum Reprod Update 1998;4(4):360-7
23. Parazzini F, Vercellini P, Panazza S, et al. Risk factors for adenomyosis. Hum Reprod 1997;12(6):1275-9
24. Campo S, Campo V, Benagiano G. Infertility and adenomyosis. Obstet Gynecol Int 2012;2012:786132
25. Kunz G, Leyendecker G. Uterine peristaltic activity during the menstrual cycle: characterization, regulation, function and dysfunction. Reprod Biomed Online 2002;4(Suppl 3):5-9
26. Kitawaki J, Noguchi T, Amatsu T, et al. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997;57(3):514-19
27. Brosens J, Verhoeven H, Campo R, et al. High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome. Hum Reprod 2004;19(2):352-6
28. Xiao Y, Li T, Xia E, et al. Expression of integrin beta3 and osteopontin in the eutopic endometrium of adenomyosis during the implantation window. Eur J Obstet Gynecol Reprod Biol 2013;170(2):419-22
29. Xiao Y, Sun X, Yang X, et al. Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. Fertil Steril 2010;94(1):85-9
30. Fischer CP, Kayisili U, Taylor HS. HOXA10 expression is decreased in endometrium of women with adenomyosis. Fertil Steril 2011;95(3):1133-6
31. Vercellini P, Consonni D, Barbara G, et al. Adenomyosis and reproductive performance after surgery for rectovaginal and colorectal endometriosis: a systematic review and meta-analysis. Reprod Biomed Online 2014;28(6):704-13
32. Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril 2011;95(7):2204-8; 2208.e1-3
33. Mechsner S, Grum B, Gericke C, et al. Possible roles of oxytocin receptor and vasopressin-1alpha receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteri. Fertil Steril 2010;94(7):2541-6
34. Liu X, Guo SW. Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis. J Obstet Gynaecol Res 2011;37(7):696-708
35. Zhang X, Lu B, Huang X, et al. Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids. Fertil Steril 2010;94(2):730-7
36. Pepas L, Deguara C, Davis C. Update on the surgical management of adenomyosis. Curr Opin Obstet Gynecol 2012;24(4):259-64
37. Popovic M, Puchner S, Berzaczy D, et al. Uterine artery embolization for the treatment of adenomyosis: a review. J Vasc Interv Radiol 2011;22(7):901-9
38. Zhang X, Li K, Xie B, et al. Effective ablation therapy of adenomyosis with ultrasound-guided high-intensity focused ultrasound. Int J Gynaecol Obstet 2014;124(3):207-11
39. Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrelreleasing intrauterine device. Fertil Steril 1997;68(3):426-9
40. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol 2013;121(4):891-6
41. Vercellini P, Consonni D, Dridi D, et al. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod 2014;29(5):964-77
42. Thalluri V, Tremellen KP. Ultrasound diagnosed adenomyosis has a negative impact on successful implantation following GnRH antagonist IVF treatment. Hum Reprod 2012;27(12):3487-92
43. Costello MF, Lindsay K, McNally G. The effect of adenomyosis on in vitro fertilisation and intra-cytoplasmic sperm injection treatment outcome. Eur J Obstet Gynecol Reprod Biol 2011;158(2):229-34
44. Sallam HN, Garcia-Velasco JA, Dias S, et al. Long-term pituitary downregulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006(1):CD004635
45. Imaoka I, Ascher SM, Sugimura K, et al. MR imaging of diffuse adenomyosis changes after GnRH analog therapy. J Magn Reson Imaging 2002;15(3):285-90
46. Khan KN, Kitajima M, Hiraki K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010;25(3):642-53
47. Mijatovic V, Florijn E, Halim N, et al. Adenomyosis has no adverse effects on IVF/ICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF/ICSI. Eur J Obstet Gynecol Reprod Biol 2010;151(1):62-5
48. Martinez-Conejero JA, Morgan M, Montesinos M, et al. Adenomyosis does not affect implantation, but is associated with miscarriage in patients undergoing oocyte donation. Fertil Steril 2011;96(4):943-50
49. Niu Z, Chen Q, Sun Y, et al. Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis. Gynecol Endocrinol 2013;29(12):1026-30
50. ClinicalTrials.gov. Registry and results database of publicly and privately supported clinical studies of human participants [Internet]. Available from: www.ClinicalTrials.gov
51. Akira S, Mine K, Kuwabara Y, et al. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis. Med Sci Monit 2009;15(1):CR1-4
52. Nie J, Lu Y, Liu X, et al. Immunoreactivity of progesterone receptor isoform B, nuclear factor kappaB, and IkappaBalpha in adenomyosis. Fertil Steril 2009;92(3):886-9
53. Mehasseb MK, Panchal R, Taylor AH, et al. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril 2011;95(7):2228-2235.e1
54. Nie J, Liu X, Guo S. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent. Reprod Sci 2010;17(11):995-1005
55. Wu Y, Shi X, Guo SW. The knockdown of progesterone receptor isoform B (PRB) promotes proliferation in immortalized endometrial stromal cells. Fertil Steril 2008;90(4):1320-3
56. Sasa H, Imai K, Suzuki A, et al. Comparison of low-dose dienogest with low-dose danazol for long-term treatment of adenomyosis. Obstet Gynecol 2014;123:97S-8S
57. Nagata C, Yanagida S, Okamoto A, et al. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. J Obstet Gynaecol Res 2012;38(4):639-44
58. Choi YS, Cho S, Lim KJ, et al. Effects of LNG-IUS on nerve growth factor and its receptors expression in patients with adenomyosis. Growth Factors 2010;28(6):452-60
59. Maia H Jr, Haddad C, Casoy J, et al. Effect of a hormone-releasing intrauterine system (Mirena((R))) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection. Int J Womens Health 2012;4:175-83
60. Maia H Jr, Maltez A, Studart E, et al. Proliferation kinetics in adenomyosis during the menstrual cycle and during oral contraceptive use. Gynecol Endocrinol 2004;18(2):101-6
61. Laoag-Fernandez JB, Maruo T, Pakarinen P, et al. Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis. Hum Reprod 2003;18(4):694-9
62. Maia H Jr, Maltez A, Coelho G, et al. Insertion of mirena after endometrial resection in patients with adenomyosis. J Am Assoc Gynecol Laparosc 2003;10(4):512-16
63. Zheng J, Xia E, Li TC, et al. Comparison of combined transcervical resection of the endometrium and levonorgestrel-containing intrauterine system treatment versus levonorgestrelcontaining intrauterine system treatment alone in women with adenomyosis: a prospective clinical trial. J Reprod Med 2013;58(7-8):285-90
64. Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009;79(3):189-93
65. Ozdegirmenci O, Kayikcioglu F, Akgul MA, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril 2011;95(2):497-502
66. Mansukhani N, Unni J, Dua M, et al. Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding? J Midlife Health 2013;4(1):31-5
67. Ishihara H, Kitawaki J, Kado N, et al. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas. Fertil Steril 2003;79(Suppl 1):735-42
68. Igarashi M, Abe Y, Fukuda M, et al. Novel conservative medical therapy for uterine adenomyosis with a danazolloaded intrauterine device. Fertil Steril 2000;74(2):412-13
69. Igarashi M. A new therapy for pelvic endometriosis and uterine adenomyosis: local effect of vaginal and intrauterine danazol application. Asia Oceania J Obstet Gynaecol 1990;16(1):1-12
70. Marjoribanks J, Proctor M, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010(1):CD001751
71. Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2013;1:CD000400
72. Badawy AM, Elnashar AM, Mosbah AA. Aromatase inhibitors or gonadotropinreleasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand 2012;91(4):489-95
73. Kimura F, Takahashi K, Takebayashi K, et al. Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist. Fertil Steril 2007;87(6):1468.e9-12
74. Chen C, Wu D, Guo Z, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropinreleasing hormone receptor. J Med Chem 2008;51(23):7478-85
75. Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, doubleblind, placebo-controlled study. Reprod Sci 2014;21(3):363-71
76. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009;94(2):545-51
77. Wang Y, Jiang X, Wang S. The influence of mifepristone to caspase 3 expression in adenomyosis. Clin Exp Obstet Gynecol 2014;41(2):154-7
78. Li H-WR, Lo SST, Ho P-C. Emergency contraception. Best Pract Res Clin Obstet Gynaecol 2014. [Epub ahead of print]
79. Mozzanega B, Gizzo S, Di Gangi S, et al. Ulipristal acetate: critical review about endometrial and ovulatory effects in emergency contraception. Reprod Sci 2014;21(6):678-85
80. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366(5):409-20
81. Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366(5):421-32
82. Donnez J, Vázquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate(∗). Fertil Steril 2014;101(6):1565-1573.e18
83. Ota H, Igarashi S, Tanaka T. Morphometric evaluation of stromal vascularization in the endometrium in adenomyosis. Hum Reprod 1998;13(3):715-19
84. Zhou Y-F, Mori T, Kudo H, et al. Effects of angiogenesis inhibitor TNP-470 on the development of uterine adenomyosis in mice. Fertil Steril 2003;80(Suppl 2):788-94
85. Streuli I, de Ziegler D, Santulli P, et al. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother 2013;14(3):291-305
86. Hauksson A, Ekstrom P, Juchnicka E, et al. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand 1989;68(1):31-4
87. Serradeil-Le Gal C, Wagnon J, Valette G, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 2002;139:197-210
88. Nie J, Liu X, Guo SW. Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol 2010;202(4):346.e1-8
89. Guo SW, Mao X, Ma Q, et al. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril 2013;99(1):231-40
90. Liu X, Guo SW. Aberrant immunoreactivity of deoxyribonucleic acid methyltransferases in adenomyosis. Gynecol Obstet Invest 2012;74(2):100-8
91. Liu X, Guo SW. A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril 2008;89(1):246-50
92. Liu X, Yuan L, Guo SW. Valproic acid as a therapy for adenomyosis: a comparative case series. Reprod Sci 2010;17(10):904-12
93. Preutthipan S, Herabutya Y. Hysteroscopic rollerball endometrial ablation as an alternative treatment for adenomyosis with menorrhagia and/or dysmenorrhea. J Obstet Gynaecol Res 2010;36(5):1031-6